A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide

Summary

The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Talquetamab

  Talquetamab will be administered as a SC injection.

• Drug
  Pomalidomide

  Pomalidomide will be administered orally.

• Drug
  Teclistamab

  Teclistamab will be administered as a SC injection.

• Drug
  Elotuzumab

  Elotuzumab will be administered intravenously.

• Drug
  Dexamethasone

  Dexamethasone will be administered either orally or intravenously.

• Drug
  Bortezomib

  Bortezomib will be administered as a SC injection.

Locations (242)